196 related articles for article (PubMed ID: 37779141)
1. Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas.
Machino H; Dozen A; Konaka M; Komatsu M; Nakamura K; Ikawa N; Shozu K; Asada K; Kaneko S; Yoshida H; Kato T; Nakayama K; Saloura V; Kyo S; Hamamoto R
Exp Mol Med; 2023 Oct; 55(10):2205-2219. PubMed ID: 37779141
[TBL] [Abstract][Full Text] [Related]
2. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
Hooda J; Novak M; Salomon MP; Matsuba C; Ramos RI; MacDuffie E; Song M; Hirsch MS; Lester J; Parkash V; Karlan BY; Oren M; Hoon DS; Drapkin R
Cancer Res; 2019 Feb; 79(4):760-772. PubMed ID: 30563893
[TBL] [Abstract][Full Text] [Related]
3. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
[TBL] [Abstract][Full Text] [Related]
4. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma.
Tangri A; Lighty K; Loganathan J; Mesmar F; Podicheti R; Zhang C; Iwanicki M; Drapkin R; Nakshatri H; Mitra S
Mol Cancer Res; 2021 Jul; 19(7):1168-1181. PubMed ID: 33753553
[TBL] [Abstract][Full Text] [Related]
5. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
6. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
7. Frequency of serous tubal intraepithelial carcinoma (STIC) in patients with high grade serous ovarian cancer.
Byun JM; Cho HJ; Lee DS; Yoon HK; Kim YN; Im DH; Kim DH; Lee KB; Sung MS; Jeong DH
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):107-111. PubMed ID: 36720520
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
Front Immunol; 2022; 13():923194. PubMed ID: 35935940
[TBL] [Abstract][Full Text] [Related]
9. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
10. Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology.
Brown Y; Hua S; Tanwar PS
Matrix Biol; 2023 Apr; 118():16-46. PubMed ID: 36781087
[TBL] [Abstract][Full Text] [Related]
11. High grade serous ovarian carcinomas originate in the fallopian tube.
Labidi-Galy SI; Papp E; Hallberg D; Niknafs N; Adleff V; Noe M; Bhattacharya R; Novak M; Jones S; Phallen J; Hruban CA; Hirsch MS; Lin DI; Schwartz L; Maire CL; Tille JC; Bowden M; Ayhan A; Wood LD; Scharpf RB; Kurman R; Wang TL; Shih IM; Karchin R; Drapkin R; Velculescu VE
Nat Commun; 2017 Oct; 8(1):1093. PubMed ID: 29061967
[TBL] [Abstract][Full Text] [Related]
12. Outcome and Management of Serous Tubal Intraepithelial Carcinoma Following Opportunistic Salpingectomy: Systematic Review and Meta-Analysis.
Ruel-Laliberté J; Kasasni SM; Oprea D; Viau M
J Obstet Gynaecol Can; 2022 Nov; 44(11):1174-1180. PubMed ID: 36099965
[TBL] [Abstract][Full Text] [Related]
13. TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer.
Lecker LSM; Berlato C; Maniati E; Delaine-Smith R; Pearce OMT; Heath O; Nichols SJ; Trevisan C; Novak M; McDermott J; Brenton JD; Cutillas PR; Rajeeve V; Hennino A; Drapkin R; Loessner D; Balkwill FR
Cancer Res; 2021 Nov; 81(22):5706-5719. PubMed ID: 34561272
[TBL] [Abstract][Full Text] [Related]
14. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
[TBL] [Abstract][Full Text] [Related]
15. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
[TBL] [Abstract][Full Text] [Related]
16. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
[TBL] [Abstract][Full Text] [Related]
17. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
[TBL] [Abstract][Full Text] [Related]
18. NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells.
Liu C; Vorderbruggen M; Muñoz-Trujillo C; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS; Karpf AR
J Ovarian Res; 2024 May; 17(1):94. PubMed ID: 38704607
[TBL] [Abstract][Full Text] [Related]
19. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
Wen J; Shi JL; Shen DH; Chen YX; Song QJ
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
[TBL] [Abstract][Full Text] [Related]
20. FBLN5 is targeted by microRNA‑27a‑3p and suppresses tumorigenesis and progression in high‑grade serous ovarian carcinoma.
Li R; Wu H; Jiang H; Wang Q; Dou Z; Ma H; Yan S; Yuan C; Yang N; Kong B
Oncol Rep; 2020 Nov; 44(5):2143-2151. PubMed ID: 32901854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
